Nerolidol and its Pharmacological Application in Treating Neurodegenerative Diseases: A Review

Author(s): Rusbene Bruno Fonseca De Carvalho* , Antonia Amanda Cardoso De Almeida , Neylon Barbosa Campelo , Daniel Ramon Oliveira Dantas Lellis , Livio Cesar Cunha Nunes .

Journal Name: Recent Patents on Biotechnology

Volume 12 , Issue 3 , 2018

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: Research on natural bioactive compounds has increased exponentially over the last decades. The discovery of new phytochemicals that possess pharmaceutical properties is useful in the development of therapeutic alternatives. The nerolidol (3,7,11-trimetil-1,6,10-dodecatrien-3-ol or 3,7,11-trimetildodeca-1,6,10-trien-3-ol) has been extensively studied for its therapeutic potential because of its pharmacological activities in the treatment of neurodegenerative diseases.

Method: All articles and patents regarding nerolidol and its pharmacological properties were revised, focusing mainly on the important properties in the treatment of neurodegenerative diseases. A thorough search in article databases (Science Direct, MEDLINE/PubMed, Scopus and Scielo) and patent database (WIPO, EPO, ESPTO, LATIPAT and INPI) was performed over the course of this study.

Results: Several studies stood out for their relevance regarding the treatment of neurodegenerative diseases. Nerolidol demonstrated anticholinesterasic, antioxidant, antinociceptive, anti-inflammatory and anxiolytic activities, thus classifying it as a promising phytochemical for the development of therapeutic drugs.

Conclusion: Analysis suggested that nerolidol is a promising target for new drugs and treatment of neurodegenerative diseases.

Keywords: Nerolidol, neurodegenerative diseases, pharmacological application, sesquiterpene, Alzheimer`s, epilepsy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 12
ISSUE: 3
Year: 2018
Page: [158 - 168]
Pages: 11
DOI: 10.2174/1872208312666171206123805
Price: $58

Article Metrics

PDF: 20
HTML: 2
EPUB: 1
PRC: 1